NIH proposes one safety-monitoring standard for all its clinical research

Under a draft policy released Nov. 2, 2026, the National Institutes of Health (NIH) would require approved safety-monitoring plans for all the clinical research it supports, including observational studies, and make independent-monitoring requirements depend on study risk.

NIH said in its announcement that the update aims to cut administrative burden that doesn’t match a study’s risk while ensuring reliable data.

The draft would update the 1998 NIH Policy for Data and Safety Monitoring, which, along with 2000 guidance on monitoring Phase 1 and Phase 2 trials, has set the baseline for how NIH-funded trials are monitored.

The draft would expand the rules from clinical trials to all NIH-supported clinical research and require the funding institute, center or office to approve monitoring plans. NIH says it would remove categorical requirements for a data and safety monitoring board (DSMB) for Phase 3 or multisite trials.

The proposed policy would cover competing grant applications, competitive revisions, contract proposals and other funding agreements, as well as IRB-approved intramural clinical research projects. An IRB is an institutional review board.

Each institute set its own bar

The 1998 policy let each NIH institute implement monitoring as it saw fit. For example, under NIH-wide rules, a formal data and safety monitoring plan is required for clinical trials but optional for other human subjects research, including observational studies, according to NIH’s grant application instructions. But some institutes do: NIDDK requires monitoring plans for observational studies, and NIAMS says large observational studies may need their own monitoring board.

ClinicalTrials.gov records show variation in reported monitoring arrangements among trials associated with NIH institutes. Among registered Phase 3 trials, including combined Phase 2/3 trials, with actual or estimated start dates from 2017 onward, the share reporting a data monitoring committee (DMC) was 100% for NEI (20 of 20 trials answering the question), 98% for NIAID (43 of 44), 96% for NICHD (49 of 51), 91% for NIA (29 of 32) and 50% for NCI (135 of 272).

The R&D World analysis used ClinicalTrials.gov data retrieved Nov. 5, 2026, covering interventional studies that list an NIH organization as lead sponsor or collaborator. It included future start dates and all trial statuses, including withdrawn and terminated studies. Registrants supply the DMC answers; the percentages exclude unanswered fields. A study could count under more than one institute. These figures describe reported committee appointments and do not establish compliance with NIH monitoring requirements.

In announcing the draft, NIH said it wants to harmonize monitoring requirements across the agency.

New requirements for non-trial studies

The biggest expansion in the draft covers non-trial clinical research. The 1998 policy required monitoring plans only for clinical trials. The draft would extend that requirement to all NIH-supported clinical research, including epidemiological and behavioral studies, outcomes research, health services research and studies of disease mechanisms.

The expansion would reach a large part of NIH’s clinical research portfolio. According to the notice, almost two-thirds of that portfolio consists of studies that are not clinical trials, and data from those studies often feed into later trials. NIH wants the same data-quality and safety standards to apply to them.

Monitoring would scale with risk, which the notice says would let NIH tier oversight to reduce administrative burden. Each study within the policy’s scope would need a plan approved before human-subject activities begin. The funding institute, center or office would have 30 days after receiving a requested plan to respond; after that, the plan would be deemed approved. Researchers would have to report plan amendments, with prior approval required for changes subject to NIH’s prior-approval rules. The notice says NIH will check compliance at regular reporting intervals, and failing to comply could lead to added award conditions or termination.

What happens next

NIH is collecting comments on this draft until Jan. 6, 2027. The draft specifies that a final policy would apply to applications submitted at least six months after final publication.

The existing NIH monitoring requirements remain applicable during the transition to any final policy.

NIH is asking commenters whether the draft improves risk-based oversight of data quality and participant safety. It also wants input on resources to help researchers comply, such as templates, model monitoring plans, a risk-assessment framework and guidance on what plans must include.

NIH also sought comment in June on a proposal to cap simultaneous research project grants per investigator. Separately, R&D World has reported on publication-cost concerns surrounding NIH’s public-access policy.